{"id":66229,"date":"2019-12-30T23:55:42","date_gmt":"2019-12-31T04:55:42","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/la-fda-accorde-une-designation-de-percee\/"},"modified":"2019-12-30T23:55:42","modified_gmt":"2019-12-31T04:55:42","slug":"la-fda-accorde-une-designation-de-percee","status":"publish","type":"post","link":"https:\/\/www.erdheim-chester.org\/fr\/la-fda-accorde-une-designation-de-percee\/","title":{"rendered":"La FDA accorde une d\u00e9signation de perc\u00e9e"},"content":{"rendered":"<p>La Food and Drug Administration (FDA) des \u00c9tats-Unis a accord\u00e9 au cobimetinib le statut de \u00ab Breakthrough Therapy Designation \u00bb pour le traitement des patients atteints de n\u00e9oplasmes histiocytaires (maladie de Rosai-Dorfman, histiocytose de Langerhans) ne pr\u00e9sentant pas de mutation BRAF V600.Erdheim-Chester maladie de Rosai-Dorfman, histiocytose de Langerhans) qui ne sont pas porteurs de la mutation <em>BRAF<\/em> V600. Il s&rsquo;agit d&rsquo;un grand pas en avant non seulement pour les patients <em>BRAF-n\u00e9gatifs de<\/em> ECD, mais aussi pour toutes les histiocytoses. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>La Food and Drug Administration (FDA) des \u00c9tats-Unis a accord\u00e9 au cobimetinib le statut de \u00ab Breakthrough Therapy Designation \u00bb pour le traitement des patients atteints de n\u00e9oplasmes histiocytaires (maladie [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":91083,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","_wds_title":"","_wds_metadesc":"","_wds_focus-keywords":"","_wds_meta-robots-adv":"","_wds_meta-robots-noindex":false,"_wds_meta-robots-nofollow":false,"_wds_meta-robots-index":false,"_wds_meta-robots-follow":false,"_wds_autolinks-exclude":false,"_wds_canonical":"","_wds_redirect":"","_wds_opengraph":[],"_wds_twitter":[],"cybocfi_hide_featured_image":"","wds_primary_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[2076],"tags":[2129],"class_list":["post-66229","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-communiques-de-presse","tag-2019-fr"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/posts\/66229","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/comments?post=66229"}],"version-history":[{"count":0,"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/posts\/66229\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/media\/91083"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/media?parent=66229"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/categories?post=66229"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/tags?post=66229"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}